1. Beeh KM, Beier J. Indacaterol: a new once daily long-acting 
beta2-adrenoceptor agonist. Core Evidence 2009; 4: 37–41.
2. Moen MD. Indacaterol in chronic obstructive pulmonary disease. Drugs 2010; 70: 2269–80.
3. Brienza NS, Amor-Carro Ó, Ramos-Barbón D. An update on the use of indacaterol in patients with COPD. Ther Adv Respir Dis 2011; 5: 29–40.
4. Yorgancioglu A. Indacaterol in chronic obstructive pulmonary disease. An update for clinicians. Ther Adv Chronic Dis 2012; 3: 25–36.
5. GOLD Guidelines. COPD Diagnosis and Management. Global Initiative for Chronic Obstructive Pulmonary Disease (2011). Available from: http://www.goldcopd.com.
6. Cazzola M, Calzetta L, Matera MG. b2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011; 163: 4–17.
7. Cazzola M, Matera MG, Lotvall J. Ultra long-acting beta2-agonists in development for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2005; 14: 775–83.
8. EMEA European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report EMA/659981/2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_
library/EPAR_Public_assessment_report/human/001114/
WC500053735.pdf. Accessed: March 21, 2012.
9. Battram C, Charlton SJ, Cuenoud B et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quino lin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006; 317: 762–70.
10. Lombardi D, Cuenoud B, Kramer SD et al. Lipid membrane interactions of indacaterol and salmeterol: Do they influence their pharmacological properties? Eur J Pharm Sci 2009; 38: 533–47.
11. Cazzola M, Calzetta L, Matera MG. Novel long-acting bronchodilators for COPD and asthma. Br J Pharmacol 2008; 155: 291–9.
12. Pontier J, Percherancier Y, Galandrin S et al. Cholesterol-dependent separation of the b2-adrenergic receptor from its partners determines signaling efficacy. Insight into nanoscale organization of signal transduction. J Biol Chem 2008; 283: 24659–72.
13. Cazzola M, Proietto A, Matera MG. Indacaterol for chronic obstructive pulmonary disease (COPD). Drugs Today (Barc) 2010; 46: 139–50.
14. Roig J, Hernando R, Mora R. Indacaterol, a novel once daily inhaled b2-adrenoreceptor agonist. Open Respir Med J 2009; 3: 27–30.
15. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125: 249–59.
16. Vogelmeier C, Kardos P, Harari S et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: 
A 6-month study. Respiry Mede 2008; 102: 1511–20.
17. van Noord JA, Aumann JL, Janssens E et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214–22.
18. Чучалин А.Г., Овчаренко С.И., Авдеев С.Н. и др. Место препарата Онбрез Бризхалер (индакатерол) в терапии хронической обструктивной болезни легких: заключение экспертного совета. Пульмонология. 2011; 6: 124–5.
19. Dahl R. Efficacy of indacaterol in COPD is maintained 
irrespective of inhaled corticosteroid (ICS) use. European Respiratory Society (ERS) Annual Congress 2011. Abstract No. P861.
20. Feldman G, Siler T, Prasad N et al. Efficacy and safety of indacaterol 150 mg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulm Med 2010; 10: 11.
21. Donohue JF, Fogarty C, Lotvall J et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
22. Kornmann O, Dahl R, Centanni S et al. Once-daily indacaterol vs twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273–9.
23. Dahl R, Chung KF, Buhl R et al. Efficacy of a new once daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010; 65: 473–9.
24. Chapman KR, Rennard SI, Dogra A et al. Long-term safety and efficacy of indacaterol, a novel long-acting b2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140: 68–75.
25. Korn S, Kerwin E, Atis S et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: A 12-week study. Respir Med 2011; 105: 719–26.
26. Buhl R, Dunn LJ, Disdier C et al. on behalf of the INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011; 38: 797–803.
27. Mahler DA, Buhl R, Owen R et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (<65 or ≥65 years) [abstract no. F93]. Am J Respir Crit Care Med 2010; 181: A4456.
28. Donohue JF, Decramer M, Owen R et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use [abstract no. F75]. Am J Respir Crit Care Med 2010; 181: A4438.
29. Kleerup EC, D’Urzo A, Owen R et al. Once-daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility [abstract no. F76]. Am J Respir Crit Care Med 2010; 181: A4439.
30. O’Donnell, Casaburi R, Vincken W et al. Effect of Indacaterol on exercise endu-rance and lung hyperinflation in COPD. Respir Med 2011; 105: 1030–6.
31. Donaldson GC, Wedzicha JA. COPD exacerbations: epidemiology. Thorax 2006; 61: 164–8.
32. Siler TM, Williams J, Yegen U et al. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med 2010; 181: A4430.
33. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J Suppl 2003; 41: 36s–45s.
34. Jones PW, Brusselle G, Dal Negro RW et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011; 105: 57–66.
35. Lipworth BJ. Antagonism of long-acting β-adrenoreceptor 
agonism. Br J Clin Pharmacol 2002; 54: 231–45.
36. Naline E, Trifilieff A, Fairhurst RA et al. Effect of indacaterol, a novel long-acting b2-agonist, on isolated human bronchi. Eur Respir J 2007; 29: 575–81.
37. Decramer M, Donohue J, Owen R et al. Indacaterol provides effective bronchodilation in patients with COPD regardless of concomitant ICS use. European Respiratory Society (ERS) Annual Congress 2010. Abstract No. P5555.
38. Mahler DA, D’Urzo A, Peckitt C et al. Combining once-daily bronchodilators in COPD: Indacaterol plus tiotropium versus tiotropium alone. Presented at American Thoracic Society (ATS) International Conference, Denver Colorado, May 2011. Am J Respir Crit Care Med 2011; 183: A1591.
39. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002; 110: S322–S328.
40. Worth H, Chung KF, Felser JM et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med 2011; 105: 571–9.

С.Н.Авдеев 

ФГУ НИИ пульмонологии ФМБА России, Москва